Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals Announces Commercial Availability of PEMFEXY™
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Tickers EGRX
Eagle Pharmaceuticals on Track to Support Submission of New Drug Application in Second Quarter 2022 for Landiolol, a Beta-1 Adrenergic Blocker
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Tickers EGRX
Eagle Pharmaceuticals Announces Commercial Availability of Vasopressin
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Tickers EGRX
Eagle Pharmaceuticals Provides 2022 Business Update and Announces Launch of Vasopressin
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Tickers EGRX
Eagle Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Tickers EGRX
Eagle Pharmaceuticals Receives 180 Days of Marketing Exclusivity for Recently Approved Vasopressin
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Tickers EGRX
Eagle Pharmaceuticals Reports that Par Has Unilaterally Withdrawn Attempt to Halt Launch of Vasopressin
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Tickers EGRX
Eagle Pharmaceuticals Receives FDA Approval for Vasopressin
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Tickers EGRX
Eagle Pharmaceuticals to Present at Piper Sandler 33rd Annual Healthcare Conference 2021
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Tickers EGRX
Eagle Pharmaceuticals Reports Third Quarter 2021 Results
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Tickers EGRX
Eagle Pharmaceuticals to Host Third Quarter 2021 Financial Results on November 9, 2021
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Tickers EGRX
Reminder: Eagle Pharmaceuticals to Host CAL02 Investor Event on September 9, 2021
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Tickers EGRX
Eagle Pharmaceuticals to Present at September Healthcare Conferences
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Tickers EGRX
Eagle Pharmaceuticals Wins Vasopressin Patent Trial
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Tickers EGRX
Eagle Pharmaceuticals Granted Additional Patent for Bendamustine Franchise
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Tickers EGRX
Eagle Pharmaceuticals Announces Worldwide Licensing Agreement with Combioxin SA for Phase 2b/3, Novel First-in-Class Antitoxin Agent CAL02 in Development for Combination Use with Antibiotics for the Treatment of Severe Pneumonia
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Tickers EGRX
Eagle Pharmaceuticals Reports Second Quarter 2021 Results
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Tickers EGRX
Eagle Pharmaceuticals Announces Licensing Agreement with AOP Orphan for U.S. Commercial Rights to Landiolol, a Beta-1 Adrenergic Blocker
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Tickers EGRX
Eagle Pharmaceuticals to Host Second Quarter 2021 Financial Results on August 9, 2021
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Tickers EGRX
Eagle Pharmaceuticals Announces FDA Maintains Prioritization of ANDA for Vasopressin
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Tickers EGRX
Eagle Pharmaceuticals Submits Response to Complete Response Letter from FDA for Vasopressin
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Tickers EGRX
Eagle Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Tickers EGRX
Eagle Pharmaceuticals to Present at the 2021 RBC Capital Markets Global Healthcare Conference
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Tickers EGRX
Eagle Pharmaceuticals Reports First Quarter 2021 Results
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Tickers EGRX
Eagle Pharmaceuticals Announces Filing of TREAKISYM (bendamustine) Rapid Infusion (“RI”) Liquid Formulation in Japan
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Tickers EGRX
Eagle Pharmaceuticals Appoints Former FDA Official and Public Health Expert Dr. Luciana Borio to its Board of Directors
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Tickers EGRX
Eagle Pharmaceuticals Announces TREAKISYM (bendamustine) Ready-to-Dilute (“RTD”) Formulation, in Combination with Rituximab for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma Receives PMDA Approval in Japan
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Tickers EGRX
Eagle Pharmaceuticals to Host First Quarter 2021 Financial Results on May 10, 2021
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Tickers EGRX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.